Top Page
Oxford BioDynamics
(LSE:OBD)
Oxford BioDynamics (OBD) vs. iShares MSCI United Kingdom ETF (EWC)
Oxford BioDynamics Business Overview & Revenue Model
Oxford BioDynamics Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.09M | 1.09M | 636.00K | 510.00K | 154.00K | 341.00K |
| Gross Profit | -6.15M | -6.15M | 289.00K | 266.00K | 116.00K | -557.00K |
| EBITDA | -9.80M | -9.80M | -10.27M | -9.84M | -6.16M | -6.43M |
| Net Income | -11.15M | -11.15M | -11.57M | -10.83M | -6.71M | -6.68M |
Balance Sheet | ||||||
| Total Assets | 8.09M | 8.09M | 12.11M | 16.13M | 11.34M | 15.38M |
| Cash, Cash Equivalents and Short-Term Investments | 1.39M | 1.39M | 2.83M | 5.25M | 999.00K | 4.34M |
| Total Debt | 5.11M | 5.11M | 5.74M | 6.44M | 6.14M | 6.59M |
| Total Liabilities | 6.97M | 6.97M | 7.75M | 10.07M | 8.76M | 8.69M |
| Stockholders Equity | 1.12M | 1.12M | 4.36M | 6.05M | 2.59M | 6.68M |
Cash Flow | ||||||
| Free Cash Flow | -7.73M | -7.73M | -10.77M | -9.01M | -6.08M | -9.01M |
| Operating Cash Flow | -7.71M | -7.71M | -10.17M | -8.29M | -5.18M | -5.92M |
| Investing Cash Flow | 756.00K | 756.00K | -1.49M | -691.00K | 1.25M | 2.83M |
| Financing Cash Flow | 6.52M | 6.52M | 8.25M | 13.42M | 2.56M | -804.00K |
Oxford BioDynamics Technical Analysis
Oxford BioDynamics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | £10.89M | -6.32 | -15.57% | ― | 13.32% | 55.07% | |
52 Neutral | £26.97M | -6.96 | -213.66% | ― | 39.88% | 81.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | £50.46M | -61.52 | -11.24% | ― | 283.74% | 78.57% | |
47 Neutral | £9.38M | -3.80 | -648.46% | ― | ― | ― | |
44 Neutral | £16.48M | -10.07 | -164.37% | ― | -11.43% | 23.40% | |
38 Underperform | £10.08M | -0.26 | -407.49% | ― | 72.17% | 79.03% |
Oxford BioDynamics Corporate Events
Oxford BioDynamics has published its annual report and accounts for the year ended 30 September 2025, making the document available electronically on its website and dispatching hard copies, including the notice of its upcoming annual general meeting, to shareholders. The AGM is scheduled to take place in Oxford on 26 January 2026, providing investors with a formal opportunity to review the company’s performance and strategy as it continues to commercialise and expand its portfolio of precision genomic diagnostic tests.
The most recent analyst rating on (GB:OBD) stock is a Sell with a £0.23 price target. To see the full list of analyst forecasts on Oxford BioDynamics stock, see the GB:OBD Stock Forecast page.
Oxford BioDynamics Plc announced its preliminary results for the year ending September 2025, highlighting significant growth in its EpiSwitch® Prostate Screening Test orders and a successful £7 million fundraising effort. The company has made strategic advancements, including a partnership with Google Cloud and ongoing discussions for third-party collaborations, positioning itself for further growth and increased shareholder value.
The most recent analyst rating on (GB:OBD) stock is a Sell with a £0.50 price target. To see the full list of analyst forecasts on Oxford BioDynamics stock, see the GB:OBD Stock Forecast page.
Oxford BioDynamics Plc announced that it will release its financial results for the year ending 30 September 2025 on 16 December 2025. This announcement highlights the company’s ongoing commitment to transparency and may impact its market positioning by providing stakeholders with insights into its financial health and operational progress.
The most recent analyst rating on (GB:OBD) stock is a Sell with a £0.50 price target. To see the full list of analyst forecasts on Oxford BioDynamics stock, see the GB:OBD Stock Forecast page.
Oxford BioDynamics Plc announced that the recent UK National Screening Committee’s draft recommendation on prostate cancer screening does not directly affect its EpiSwitch PSE test. Despite this, the company has reported six consecutive months of record sales for the PSE test in the US and private healthcare in the UK, indicating strong market performance and growth potential.
The most recent analyst rating on (GB:OBD) stock is a Sell with a £0.50 price target. To see the full list of analyst forecasts on Oxford BioDynamics stock, see the GB:OBD Stock Forecast page.
Oxford BioDynamics Plc has announced the grant of 170,000,000 options over its ordinary shares to its employees and advisers, including directors and PDMRs. This grant, which is part of the company’s 2016 Employee and Non-Employee Share Option Plans, is set at an exercise price of 0.61p per share, a 100% premium over the previous closing price. The vesting of these options is staggered over a period of up to two years, with some options becoming exercisable immediately and others over the next two years, potentially impacting the company’s stock value and stakeholder interests.
The most recent analyst rating on (GB:OBD) stock is a Sell with a £0.50 price target. To see the full list of analyst forecasts on Oxford BioDynamics stock, see the GB:OBD Stock Forecast page.
Oxford BioDynamics PLC announced the successful passing of resolutions at its General Meeting, which facilitates the issuance of over 2.3 billion new ordinary shares as part of a significant fundraising effort. This move is expected to enhance the company’s trading position on AIM and increase its total voting rights, impacting stakeholders’ interests and potentially strengthening its market presence.
The most recent analyst rating on (GB:OBD) stock is a Sell with a £0.50 price target. To see the full list of analyst forecasts on Oxford BioDynamics stock, see the GB:OBD Stock Forecast page.
Oxford BioDynamics has announced a fundraising initiative to raise £7 million through a placing and subscription of new ordinary shares. This funding is crucial for the company to support its operations and pursue additional business development opportunities. The funds will help the company continue its growth in PSE test sales, further develop its EpiSwitch KnowledgeBase in partnership with Google Cloud, and engage in third-party partnerships and collaborations. The fundraising is contingent on shareholder approval at a general meeting, and failure to secure this funding could necessitate alternative financial arrangements or a potential sale of the business.
The most recent analyst rating on (GB:OBD) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on Oxford BioDynamics stock, see the GB:OBD Stock Forecast page.
Oxford BioDynamics has been highlighted in a new report by Prostate Cancer Research, which supports the feasibility of a targeted prostate cancer screening program in the UK. The report recommends the inclusion of emerging technologies like OBD’s EpiSwitch PSE blood test in the NHS, citing its potential to significantly reduce false positives and unnecessary diagnostic procedures. The EpiSwitch PSE test, with its high specificity, could decrease the demand for MRI and biopsy procedures, thereby saving costs for the NHS and making large-scale screening more practical.
The most recent analyst rating on (GB:OBD) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on Oxford BioDynamics stock, see the GB:OBD Stock Forecast page.
Oxford BioDynamics has developed a groundbreaking blood test for diagnosing Chronic Fatigue Syndrome (CFS) with a high accuracy of 96%, offering a reliable diagnostic tool for a condition that affects millions globally and has long been misunderstood. This advancement, achieved using the company’s EpiSwitch® 3D genomics platform, not only promises to improve diagnosis and management of CFS but also paves the way for similar tests for conditions like long Covid, enhancing Oxford BioDynamics’ positioning in the precision diagnostics industry.
The most recent analyst rating on (GB:OBD) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on Oxford BioDynamics stock, see the GB:OBD Stock Forecast page.